Covid-stricken US still causing Lundbeck problems

While sales growth of Lundbeck's core products has stabilized well in Europe and international markets following Covid-19's peak, sales of several products in the US are still lagging – and the setback from Northera was bigger than foreseen.

Photo: Gregers Tycho/ERH

Hit harder and moving slower than expected – these are two of the main tendencies in the US that affected Lundbeck's second quarter.

The company is far more heavily impacted by the loss of its patent on drug Northera than management had first anticipated, and uncertainties caused by Covid-19 also mean that normalization is not moving as swiftly as Chief Executive Deborah Dunsire and Chief Financial Officer Anders Göetzsche had hoped.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs